These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Istvan ES Am Heart J; 2002 Dec; 144(6 Suppl):S27-32. PubMed ID: 12486413 [TBL] [Abstract][Full Text] [Related]
4. Explication of interactions between HMGCR isoform 2 and various statins through In silico modeling and docking. Karthik MV; Satya Deepak MV; Shukla P Comput Biol Med; 2012 Feb; 42(2):156-63. PubMed ID: 22177940 [TBL] [Abstract][Full Text] [Related]
5. Exploring Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies. Dinesh N; Pallerla DS; Kaur PK; Kishore Babu N; Singh S Microb Pathog; 2014 Jan; 66():14-23. PubMed ID: 24239940 [TBL] [Abstract][Full Text] [Related]
6. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening. Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841 [TBL] [Abstract][Full Text] [Related]
7. Recombinant 3-Hydroxy 3-Methyl Glutaryl-CoA Reductase from Candida glabrata (Rec-CgHMGR) Obtained by Heterologous Expression, as a Novel Therapeutic Target Model for Testing Synthetic Drugs. Andrade-Pavón D; Cuevas-Hernández RI; Trujillo-Ferrara JG; Hernández-Rodríguez C; Ibarra JA; Villa-Tanaca L Appl Biochem Biotechnol; 2017 Aug; 182(4):1478-1490. PubMed ID: 28138930 [TBL] [Abstract][Full Text] [Related]
8. On the inhibitor effects of bergamot juice flavonoids binding to the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) enzyme. Leopoldini M; Malaj N; Toscano M; Sindona G; Russo N J Agric Food Chem; 2010 Oct; 58(19):10768-73. PubMed ID: 20843083 [TBL] [Abstract][Full Text] [Related]
9. Insight into the mechanism of polyphenols on the activity of HMGR by molecular docking. Islam B; Sharma C; Adem A; Aburawi E; Ojha S Drug Des Devel Ther; 2015; 9():4943-51. PubMed ID: 26357462 [TBL] [Abstract][Full Text] [Related]
10. The structure of the catalytic portion of human HMG-CoA reductase. Istvan ES; Deisenhofer J Biochim Biophys Acta; 2000 Dec; 1529(1-3):9-18. PubMed ID: 11111074 [TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. Istvan ES; Palnitkar M; Buchanan SK; Deisenhofer J EMBO J; 2000 Mar; 19(5):819-30. PubMed ID: 10698924 [TBL] [Abstract][Full Text] [Related]
12. Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations. da Costa RF; Freire VN; Bezerra EM; Cavada BS; Caetano EW; de Lima Filho JL; Albuquerque EL Phys Chem Chem Phys; 2012 Jan; 14(4):1389-98. PubMed ID: 22159045 [TBL] [Abstract][Full Text] [Related]
13. The 3-hydroxy-3-methylglutaryl coenzyme-A reductases from fungi: a proposal as a therapeutic target and as a study model. Andrade-Pavón D; Sánchez-Sandoval E; Rosales-Acosta B; Ibarra JA; Tamariz J; Hernández-Rodríguez C; Villa-Tanaca L Rev Iberoam Micol; 2014; 31(1):81-5. PubMed ID: 24270073 [TBL] [Abstract][Full Text] [Related]
14. IAF, QGF, and QDF Peptides Exhibit Cholesterol-Lowering Activity through a Statin-like HMG-CoA Reductase Regulation Mechanism: In Silico and In Vitro Approach. Silva M; Philadelpho B; Santos J; Souza V; Souza C; Santiago V; Silva J; Souza C; Azeredo F; Castilho M; Cilli E; Ferreira E Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681729 [TBL] [Abstract][Full Text] [Related]
15. Crystal structure of archaeal HMG-CoA reductase: insights into structural changes of the C-terminal helix of the class-I enzyme. Vögeli B; Shima S; Erb TJ; Wagner T FEBS Lett; 2019 Mar; 593(5):543-553. PubMed ID: 30702149 [TBL] [Abstract][Full Text] [Related]
16. Binding thermodynamics of statins to HMG-CoA reductase. Carbonell T; Freire E Biochemistry; 2005 Sep; 44(35):11741-8. PubMed ID: 16128575 [TBL] [Abstract][Full Text] [Related]
17. Specific inhibitions of annonaceous acetogenins on class II 3-hydroxy-3-methylglutaryl coenzyme A reductase from Streptococcus pneumoniae. Feng L; Zhou L; Sun Y; Gui J; Wang X; Wu P; Wan J; Ren Y; Qiu S; Wei X; Li J Bioorg Med Chem; 2011 Jun; 19(11):3512-9. PubMed ID: 21550257 [TBL] [Abstract][Full Text] [Related]
18. Characterization of an HMG-CoA reductase from Listeria monocytogenes that exhibits dual coenzyme specificity. Theivagt AE; Amanti EN; Beresford NJ; Tabernero L; Friesen JA Biochemistry; 2006 Dec; 45(48):14397-406. PubMed ID: 17128979 [TBL] [Abstract][Full Text] [Related]
19. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]